

Risk Factors for a Second Episode of Hemoptysis

Nobuhiko Seki^{1,2}, Go Shiozaki¹, Mayuko Ota¹, Shuji Ota^{1,2}, Reishi Seki^{1,3}, Takashi Seto^{1,4}, Kazutsugu Uematsu^{1,5} and Kenji Eguchi^{1,2}

¹Division of Medical Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.

²Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan. ³Department of Laboratory Medicine, Isehara Kyodo Hospital, Isehara, Kanagawa, Japan. ⁴Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan. ⁵Division of Pulmonary Medicine, Saitama Medical Center, Kawagoe, Saitama, Japan.

Abstract

Objectives: Hemoptysis is an alarming symptom of underlying lung disease. Clinicians are often unsure how to deal with and follow up patients who have had a single episode of hemoptysis, especially if the cause remains unknown despite thorough examination, because a second, more severe episode of hemoptysis might occur despite an apparently stable condition. Investigations were done, using multivariate analyses, to see whether several clinical factors present during an initial episode of hemoptysis could be used to predict a second episode.

Subjects and Methods: Eighty patients with an initial episode of hemoptysis who underwent both computed tomographic and bronchoscopic examinations from 2003 through 2005 were reviewed.

Results: The isolation of bacteria from bronchial lavage fluid (odds ratio 13.5, $P = 0.001$) and the failure to determine the cause of the initial episode of hemoptysis (odds ratio 7.0, $P = 0.014$) were significant independent predictors of a second episode of hemoptysis. Subset analysis showed that isolation of either *Pseudomonas aeruginosa* or *Haemophilus influenzae* increased the likelihood of a second episode of hemoptysis ($P = 0.077$), even if colonization, representing host-bacterial equilibrium, had occurred. Furthermore, the failure to determine the etiology of an initial episode of hemoptysis was associated with an increased risk of a massive second episode ($P = 0.042$), regardless of the volume of the initial episode.

Conclusions: In patients with bacterial colonization of the respiratory tract or an initial episode of hemoptysis of unknown etiology, there is an increased possibility of a second episode of hemoptysis.

Keywords: bacterial colonization, bronchial lavage, recurrent hemoptysis, risk factors, unknown etiology

Introduction

Hemoptysis is an alarming symptom of underlying lung disease. Problems in treating hemoptysis include the large number of possible causes and variations in the reported prevalence.^{1–11} Another problem is the possibility of a second episode of hemoptysis after the initial active bleeding has been stopped with cause-specific treatment. Unfortunately, a second episode of hemoptysis may be severe despite the initial episode being an apparently isolated production of slightly blood streaked sputum.^{12,13} Therefore, clinicians are often unsure on how to deal with and follow up patients who have had a single episode of hemoptysis, especially if the cause remains unknown despite thorough examinations, including computed tomography (CT) and bronchoscopy. However, most published studies of hemoptysis deal with a wide range of possible causes with various rates of prevalence, diagnostic procedures, and methods of evaluating treatment.

In the present study, investigations were done using multivariate analyses, to see whether any of the several clinical factors present during an initial episode of hemoptysis are useful predictors of a second episode of hemoptysis.

Subjects and Methods

Medical records of patients presenting with an initial episode of hemoptysis at the university hospital were reviewed. Eighty consecutive patients who had undergone both chest CT and bronchoscopic

Correspondence: Nobuhiko Seki, Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan. Tel: +81-(3)-3964-1211; Ext: 1587; Fax: +81-(3)-3964-7094; Email: nseki@med.teikyo-u.ac.jp



Copyright in this article, its metadata, and any supplementary data is held by its author or authors. It is published under the Creative Commons Attribution By licence. For further information go to: <http://creativecommons.org/licenses/by/3.0/>.

examinations from January 2003 through December 2005 were evaluated. In this institution, high-resolution CT scans are routinely performed if a conventional CT scan suggests an abnormality. Furthermore, bronchial lavage for culture of microorganisms, polymerase chain reaction of mycobacterium, and cytologic examinations are performed in association with bronchoscopic examinations. Endobronchial or transbronchial biopsy was performed in relevant cases. Chest angiography was indicated in a limited number of cases of severe hemoptysis requiring embolotherapy. Patients with bleeding from the upper airway were excluded from this study. The institutional review board of this hospital did not require its approval or patient informed consent for a retrospective study of case records.

The cause of hemoptysis was determined on the basis of all available clinical data, chest CT, and bronchoscopic findings. The isolation of bacteria from the bronchial lavage fluid, accompanied by respiratory signs and symptoms (increased sputum production or cough, fever, chest CT findings consistent with a new pulmonary process, or changes in chest sounds), was considered as infection, whereas a state in which host defenses limited the activity of bacteria and therefore such respiratory signs and symptoms were absent was considered as colonization (host-bacterial equilibrium).¹⁴ Bronchitis was diagnosed when respiratory signs and symptoms consistent with the upper airway infection were present and when bleeding was absent on bronchoscopic examination.⁸ Bronchiectasis was diagnosed when dilated distal airways larger than the accompanying pulmonary arteries were visualized on high-resolution CT images. Abnormalities were noted on chest CT images by consultant radiologists; abnormalities found on high-resolution CT images included focal bronchial abnormalities (wall thickening, bronchiectasis, and interruption), infiltration, cavitation, scattered acinar nodules, and hilar masses. Cases of hemoptysis for which a cause could not be determined were considered to be of unknown etiology, even if bacterial colonization was observed.

The patient data collected included age, sex, smoking history, blood pressure, history of anticoagulant therapy, chest CT findings, type of bacteria isolated with bronchial lavage, etiology, time to recurrent hemoptysis, amounts of initial and recurrent hemoptysis, and treatment (Table 1). Hemoptysis was defined as recurrent when a second

episode of hemoptysis had occurred after the initial episode had resolved spontaneously or with treatment. On the basis of the amount of active bleeding, cases were divided into three groups: trivial (blood-streaked sputum), moderate (<500 mL/24 hours), and massive (≥ 500 mL/24 hours).⁸ Conservative treatment was attempted first in all patients when appropriate. Follow-up information of all the patients was updated in May 2007.

The relationships between categorical variables were assessed with Fisher's exact probability test or the Chi-square test as appropriate. The difference in mean between groups was evaluated with the Mann-Whitney U-test. Multivariate logistic regression analysis was performed to identify significantly independent risk factors for the second episode of hemoptysis. All calculations were performed with Stat View 5.0 J software (SAS Institute Inc., Cary, NC). Statistical significance was indicated by *P* values less than 0.05.

Results

The characteristics of the 80 patients are shown in Table 1. Active and inactive bacteria were isolated from bronchial lavage fluid in 13 (16%) cases. Despite further examination, no diagnosis was established in 21 (26%) cases. The initial treatment was conservative in 77 (96%) cases of trivial or moderate hemoptysis and embolotherapy was done in 3 (4%) cases of massive hemoptysis. During the follow-up period of 6.5 ± 9.5 months (mean \pm standard deviation; range, 0.5–36.8 months), hemoptysis recurred in 21 (26%) cases. Multivariate logistic regression analysis showed that, of the 10 clinical factors examined (Table 1), isolation of bacteria from bronchial lavage fluid (odds ratio 13.5, $P = 0.001$) and an initial episode of hemoptysis of unknown etiology (odds ratio 7.0, $P = 0.014$) were significant independent risk factors for recurrent hemoptysis.

The most common causes of the initial episode of hemoptysis (Table 2) were, in descending order, bronchitis (22 cases, 27%), "unknown etiology" (21 cases, 26%), bronchiectasis (15 cases, 19%), and infection (pneumonia, abscess, aspergilloma, and tuberculosis: 11 cases, 14%). Other causes were primary squamous cell lung cancer (3 cases, 4%), hemorrhagic diathesis (3 cases, 4%), bronchial vascular abnormality (2 cases, 3%), bronchial atresia (1 case, 1%), pulmonary sequestration (1 case, 1%), and tracheal ulcer (1 case, 1%). The diagnosis of bronchial vascular abnormality was

Table 1. Patients' characteristics for the prediction of recurrent hemoptysis.

Variable	Total (n = 80)	Initial episode only (n = 59)	Recurrent cases (n = 21)	Odds ratio	95% CI	P*
Age (years)						
<60/≥60	39/41	31/28	8/13			NS
Gender						
Female/male	17/63	13/46	4/17			NS
Smoking						
Smoker/nonsmoker	50/30	40/19	10/11			NS
Blood pressure (mmHg)						
<160/≥160	64/16	47/12	17/4			NS
Anticoagulant therapy						
No/yes	71/9	53/6	18/3			NS
Chest CT abnormality						
Yes/no	55/25	41/18	14/7			NS
Bacteria from bronchial lavage						
Negative/positive	67/13	54/5	13/8	13.5	2.8–66.6	0.001
Etiology						
Known/unknown	59/21	46/13	13/8	7.0	1.5–33.1	0.014
Amount of initial bleeding						
Trivial/moderate or massive	37/43	27/32	10/11			NS
Initial treatment						
Conservative/embolotherapy	77/3	56/3	21/0			NS

Abbreviations: CI, confidence interval; NS, not significant.

*Multivariate logistic regression analysis.

established in two cases when angiography and subsequent embolotherapy were performed in three patients with an initial episode of massive hemoptysis. The percentages of etiologies did not differ significantly between recurrent cases of hemoptysis with those who presented with only one episode.

Fifteen species of bacteria were isolated from bronchial lavage fluid in 13 (16%) cases (Table 3). Patients with recurrent hemoptysis were more likely to have *P. aeruginosa* or *H. influenzae* in bronchial lavage fluid than were patients with a single episode of hemoptysis (Fisher's exact probability test, $P = 0.077$). Recurrent hemoptysis was attributed to one case each of bronchitis and lung abscess where bacterial infection was present, and to one case each of bronchiectasis and to tuberculosis, to aspergillosis in two cases, and to

an unknown cause in two cases when bacterial colonization was present.

Details of the second episode of hemoptysis are shown in Table 4. In these 21 cases, the mean time to recurrence was 3.9 ± 8.3 months (range, 0.5–36.6 months). Although massive bleeding did not occur during the first episode in these cases, massive bleeding requiring embolotherapy occurred with the second episode in three cases of unknown etiology. When each variable was compared between cases of recurrent hemoptysis of known and unknown etiology, neither time to recurrence nor the amount of initial bleeding differed significantly (Mann-Whitney's U-test and Fisher's exact probability test, respectively). However, massive bleeding in the second episode of hemoptysis and subsequent embolotherapy were significantly

Table 2. Etiology of initial hemoptysis.

	All cases (n = 80)	Initial episode only (n = 59)	Recurrent cases (n = 21)	P
Known				NS*
Bronchitis	22	17	5	
Bronchiectasis	15	12	3	
Infection	11	7	4	
pneumonia	3	3	0	
abscess	1	0	1	
aspergilloma	3	1	2	
tuberculosis	4	3	1	
Others	11	10	1	
lung cancer	3	3	0	
hemorrhagic diathesis	3	2	1	
bronchial vascular abnormality	2	2	0	
pulmonary sequestration	1	1	0	
bronchial atresia	1	1	0	
tracheal ulcer	1	1	0	
Unknown	21	13	8	

*In etiology known cases, disease distributions between initial episode only versus recurrent groups showed no significant difference by Chi-square test.

more common when the etiology was unknown (Fisher's exact probability test, $P = 0.042$ and $P = 0.042$, respectively). The final diagnoses after the second episode were squamous cell lung cancer arising from a segmental bronchus in one case and bronchial vascular abnormality in two cases.

Discussion

The present study with multivariate analysis has demonstrated that isolation of bacteria from

bronchial lavage fluid and an initial episode of hemoptysis of unknown etiology are independent predictors of a second episode of hemoptysis. Furthermore, subset analysis has shown that isolation of either *P. aeruginosa* or *H. influenzae* from bronchial lavage fluid tends to increase the risk of recurrent hemoptysis, even in cases of colonization. In addition, episodes of hemoptysis of unknown etiology, regardless of the amount of bleeding, were more likely to recur as massive bleeding. The results of this analysis are credible

Table 3. Bacteria isolated from bronchial lavage fluid.

	All cases (n = 15)	Initial episode only (n = 5)	Recurrent cases (n = 10)	P
<i>Pseudomonas aeruginosa</i>	6*	1	5*	0.077†
<i>Haemophilus influenzae</i>	5	1	4	
<i>Staphylococcus aureus</i>	1	1	0	
<i>Escherichia coli</i>	1	1	0	
<i>Acinetobacter baumannii</i>	1	1	0	
<i>Enterobacter cloacae</i>	1	0	1	

**Haemophilus influenzae* was isolated simultaneously in one case, and *Enterobacter cloacae* in another.

†The combined *Pseudomonas aeruginosa* and *Haemophilus influenzae* versus the others were compared between initial episode only versus recurrent groups by Fisher's exact probability test.

Table 4. Details of the second episode of hemoptysis according to initial etiology.

	Total (n = 21)	Known (n = 13)	Unknown (n = 8)	P
Time to recurrence				
Months, mean \pm SD	3.9 \pm 8.3	4.0 \pm 9.9	3.6 \pm 5.1	NS*
Amount of initial bleeding				
Trivial-moderate/massive	21/0	13/0	8/0	NS†
Amount of recurrent bleeding				
Trivial-moderate/massive	18/3	13/0	5/3	0.042†
Treatment on recurrence				
Conservative/embolotherapy	18/3	13/0	5/3	0.042†

Abbreviations: SD, standard deviation; NS, not significant.

*Mann-Whitney U-test.

†Fisher's exact probability test.

because the series included patients with a single episode of hemoptysis who were followed-up for an average of 6.5 months at a single institution.

Previous studies have shown that the most common causes of hemoptysis are lung cancer, bronchiectasis, bronchitis, and infection.^{1,2} However, the frequencies of these causes vary with the characteristics of the patient population, the geographic location, and the date of study. A review by Fidan et al. of nine series which included 1297 cases of hemoptysis has shown that the mean rates of these common causes are as follows: lung cancer 25% (range, 3%–48%); bronchiectasis 15% (range, 1%–29%); bronchitis, 15% (range, 5%–37%); pneumonia, 10% (range, 1%–16%); tuberculosis, 7% (range, 1%–18%); unknown etiology, 11% (range, 1%–25%); and other causes 17% (range, 2%–28%).¹⁰ In this study, the rate of lung cancer was extremely low (4%) and was similar to that (3%) reported by Souders and Smith,³ whereas the rate of unknown etiology was extremely high (26%) and was similar to that (25%) reported by Abal et al.⁹ This result might be explained, in part, by the inclusion in this study, only of those patients with a single episode of hemoptysis and being concerned with the etiology of only this episode. In contrast, previous studies have included as high as 40% of patients with recurrent hemoptysis and have based their analyses on final diagnoses.^{9,10–12} Furthermore, in three cases in the present study, hemoptysis was diagnosed as being of unknown etiology after the initial episode, but was found to be due to squamous cell lung cancer or bronchial vascular abnormality after recurrence. Herth et al. have also reported that lung cancer was later found to be present in 6% of patients with an initial episode of

hemoptysis of unknown etiology.¹⁵ Therefore, a relatively high rate of cases with unknown etiology, despite thorough investigation without routine angiography, is quite plausible.

Among cases in which the etiology could be determined, no significant differences were seen in the frequencies of diagnosed causes between patients with only one episode of hemoptysis and those with recurrent hemoptysis (Table 2); in contrast, Fidan et al. have found that recurrent hemoptysis occurred at a significantly higher rate only in patients with bronchiectasis.¹⁰ In contrast, in this study, an initial episode of unknown etiology was an independent predictor of recurrent hemoptysis. The validity of this finding is supported by the following reasons. If the etiology is determined at the initial episode of hemoptysis, appropriate treatment would be given. However, if the cause is not established at the initial episode, appropriate treatment would not be given and a second episode might be inevitable as the underlying disease progresses; for example, occult lung cancer and potential vascular abnormality might not be diagnosed and treated without cause-specific modalities.

The second independent predictor for recurrent hemoptysis is the presence of bacteria in the bronchial lavage fluid during the first episode of hemoptysis. Bacteria were present at this initial phase in 8 of the 21 cases with recurrent hemoptysis. Bacteria could not be isolated again in all recurrent cases during a second episode of hemoptysis because bronchoscopy for bronchial lavage was not always available for all patients with recurrent hemoptysis. The aim of this study was to investigate whether, the several clinical factors present

during the initial episode of hemoptysis are useful predictors of a second episode of hemoptysis.

Fifteen species of bacteria were isolated from bronchial lavage fluid. However, in most cases colonization by either *H. influenzae* or *P. aeruginosa* was only found. The bacteria that most often colonize the diseased lung are *H. influenzae* (22%) in chronic bronchitis,¹⁶ *H. influenzae* (22%) and *P. aeruginosa* (16%) in bronchiectasis,¹⁷ *S. aureus* (18%) and *P. aeruginosa* (15%) in tuberculosis,¹⁸ and *H. influenzae* (35%), *Streptococcus pneumoniae* (13%), and *P. aeruginosa* (9%) in lung cancer.¹⁹ Therefore, colonizing *H. influenzae* and *P. aeruginosa* were the bacteria most frequently isolated in this study; however, the numbers of positive cultures of bacteria other than *H. influenzae* and *P. aeruginosa* were too small to draw definite conclusions about the relative likelihood of recurrent hemoptysis on the basis of species of bacteria (Table 3, $P = 0.077$).

With regard to the relationship between bacterial colonization and bronchial inflammatory response, Angrill et al. have demonstrated through studies of patients with clinically stable bronchiectasis that the active neutrophilic bronchial inflammatory response is enhanced by bacterial colonization in a bacterial load-dependent manner but is apparently compartmentalized and cannot be accurately detected with hematologic studies.¹⁷ Moreover, Wilson et al. reviewed previous studies of *H. influenzae* and *P. aeruginosa* and found that colonization readily progresses to infection if host defenses are impaired.²⁰ Furthermore, Chan et al. have shown that lung permeability is increased by bacterial colonization of the respiratory tract.²¹ Therefore, in patients with underlying respiratory disease, the enhanced bronchial inflammatory response to bacterial colonization or infection can cause hemoptysis. In fact, Shirai et al. and Faulkner et al. have reported that superimposed bacterial colonization or infection usually accompanies episodes of hemoptysis in patients with tuberculosis and pulmonary aspergilloma, respectively.^{18,22} These findings suggest that treating bacterial colonization or infection might reduce the odds ratio for the development of the second episode of hemoptysis. This possibility is consistent with the conclusion of Angrill et al.¹⁷

In this study, the mean time to recurrence was approximately four months in patients with recurrent hemoptysis regardless of etiology. Similarly, Ayed has reported that hemoptysis

recurs within six months.¹² However, it is amazing that lung emboli (up to 26% have hemoptysis) and heart and vascular diseases of any type did never cause hemoptysis within the three year observation period. This might be due to the high number of unknown causes. In two patients in whom the etiology of the initial episode was unknown but later turned out to be bronchial vascular abnormality, the time to recurrence was 2.7 months and 4.3 months.

In these patients with recurrent hemoptysis, none had had a previous episode of massive hemoptysis as Ayed has reported that most initial episodes of hemoptysis are mild.¹² Furthermore, massive bleeding during the second episode of hemoptysis was significantly more common in patients in whom the etiology of the initial episode, was unknown regardless of the amount of bleeding. No known previous study has determined the causes of an initial episode of hemoptysis that are most often associated with a massive second episode of hemoptysis; however, massive initial episodes of hemoptysis were most often caused by bronchiectasis and tuberculosis, and 10% were of unknown etiology.^{12,23} In this study, patients with a massive second episode of hemoptysis following an initial episode of unknown etiology, final diagnoses were lung cancer in one patient and bronchial vascular abnormality in two patients. These conditions can be life threatening through both progression and massive bleeding.²³ Therefore, if the etiology of hemoptysis remains unknown after bronchiectasis and infection have been ruled out, the possibility of occult lung cancer or vascular malformation might be considered.

Finally, to date, the prediction of recurrent hemoptysis has also been addressed by several other authors.²⁴⁻²⁶ Jeong et al. have reported the CT findings to predict recurrent hemoptysis in 58 patients who underwent bronchial artery embolization due to massive hemoptysis. By multivariate analysis, the total number of dilated bronchial and nonbronchial systemic arteries was a significant CT variable associated with the recurrence of hemoptysis. Ozgul et al. have reported the clinical findings to predict recurrent hemoptysis in 203 patients with hemoptysis. By univariate analysis, hemoptysis lasting more than five days was a significant predictive factor for a second episode of hemoptysis. However, multivariate analysis indicated no positive risk factors. Instead, lung cancer was shown to be a negative

risk factor. Furthermore, Serasli et al. have reported the observational results, in terms of etiology, for recurrent hemoptysis in 20 patients who underwent bronchial artery embolization due to massive hemoptysis. In patients with bronchiectasis, aspergillomas, tuberculosis, malignancy, and cystic fibrosis, the relapse was due to aspergillomas, lung cancer and tuberculosis. The originality of this report, is based mainly on the method of examining clinical factors and the bacterial colonization with multivariate analysis. Therefore, it is believed that this report will be useful as well, when clinicians deal with and follow-up patients who have had an initial episode of hemoptysis.

In conclusion, there is evidence that isolation of bacteria from bronchial lavage fluid and an initial episode of hemoptysis of unknown etiology are independent risk factors for a second episode of hemoptysis. However, the relatively small number and retrospective nature of the study might limit the conclusions and require further clinical studies.

Conflict of Interest

All authors of this study, declare that there is no financial or personal relationships with other people or organizations that could inappropriately influence (bias) this work.

References

1. Corder R. Hemoptysis. *Emerg Med Clin North Am.* 2003;21:421–35.
2. Bidwell JL, Pachner RW. Hemoptysis: diagnosis and management. *Am Fam Physician.* 2005;72:1253–60.
3. Souders CR, Smith AT. The clinical significance of hemoptysis. *N Engl J Med.* 1952;247:790–3.
4. Moersch HJ. Clinical significance of hemoptysis. *J Am Med Assoc.* 1952;148:1461–5.
5. Santiago S, Tobias J, Williams AJ. A reappraisal of the causes of hemoptysis. *Arch Intern Med.* 1991;151:2449–51.
6. Johnston H, Reisz G. Changing spectrum of hemoptysis. Underlying causes in 148 patients undergoing diagnostic flexible fiberoptic bronchoscopy. *Arch Intern Med.* 1989;149:1666–8.
7. McGuinness G, Beacher JR, Harkin TJ, Garay SM, Rom WN, Naidich DP. Hemoptysis: prospective high-resolution CT/bronchoscopic correlation. *Chest.* 1994;105:1155–62.
8. Hirshberg B, Biran I, Glazer M, Kramer MR. Hemoptysis: etiology, evaluation, and outcome in a tertiary referral hospital. *Chest.* 1997;112:440–4.
9. Abal AT, Nair PC, Cherian J. Haemoptysis: aetiology, evaluation and outcome—a prospective study in a third-world country. *Respir Med.* 2001;95:548–52.
10. Fidan A, Özdoğan S, Oruç O, Salepci B, Ocal Z, Çağlayan B. Hemoptysis: a retrospective analysis of 108 cases. *Respir Med.* 2002;96:677–80.
11. Wong CM, Lim KH, Liam CK. The causes of haemoptysis in Malaysian patients aged over 60 and the diagnostic yield of different investigations. *Respirology.* 2003;8:65–8.
12. Ayed A. Pulmonary resection for massive hemoptysis of benign etiology. *Eur J Cardiothorac Surg.* 2003;24:689–93.
13. Endo S, Otani S, Saito N, Hasegawa T, Kanai Y, Sato Y, et al. Management of massive hemoptysis in a thoracic surgical unit. *Eur J Cardiothorac Surg.* 2003;23:467–72.
14. Barker AF. Bronchiectasis. *N Engl J Med.* 2002;346:1383–93.
15. Herth F, Ernst A, Becker HD. Long-term outcome and lung cancer incidence in patients with hemoptysis of unknown origin. *Chest.* 2001;120:1592–4.
16. Monsó E, Rosell A, Bonet G, Manterola J, Cardona PJ, Ruiz J, et al. Risk factors for lower airway bacterial colonization in chronic bronchitis. *Eur Respir J.* 1999;13:338–42.
17. Angrill J, Agustí C, De Celis R, Filella X, Rañó A, Elena M, et al. Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. *Am J Respir Crit Care Med.* 2001;164:1628–32.
18. Shirai M, Hayakawa H, Uchiyama H, Chida K, and Nakamura H. Clinical significance of potential pathogenic microorganisms of sputum in patients with pulmonary tuberculosis. *Respirology.* 2001;6:311–5.
19. Ioanas M, Angrill J, Baldo X, Arancibia F, Gonzalez J, Bauer T, et al. Bronchial bacterial colonization in patients with resectable lung carcinoma. *Eur Respir J.* 2002;19:326–32.
20. Wilson R, Dowling RB, Jackson AD. The biology of bacterial colonization and invasion of the respiratory mucosa. *Eur Respir J.* 1996;9:1523–30.
21. Chan TB, Arm JP, Anderson J, Eiser NM. Pulmonary epithelial permeability in bronchiectasis. *Br J Dis Chest.* 1988;82:56–63.
22. Faulkner SL, Vernon R, Brown PP, Fisher RD, Bender HW Jr. Hemoptysis and pulmonary aspergilloma: operative versus nonoperative treatment. *Ann Thorac Surg.* 1978;25:389–92.
23. Revel MP, Fournier LS, Hennebique AS, Cuenod CA, Meyer G, Reynaud P, et al. Can CT replace bronchoscopy in the detection of the site and cause of bleeding in patients with large or massive hemoptysis? *AJR Am J Roentgenol.* 2002;179:1217–24.
24. Jeong YJ, Kim CW, Kim KI, Shin SM, Seo IJ, Lee IS, et al. Prediction of recurrent hemoptysis with MDCT angiography. *J Comput Assist Tomogr.* 2006;30:662–8.
25. Özgül MA, Turna A, Yildiz P, Ertan E, Kahraman S, Yilmaz V. Risk factors and recurrence pattern in 203 pts with hemoptysis. *Tuberk Toraks.* 2006;54:243–8.
26. Serasli E, Kalpakidis V, Iatrou K, Tsara V, Siopi D, Christaki P. Percutaneous bronchial artery embolization in the management of massive hemoptysis in chronic lung diseases. Immediate and long-term outcomes. *Int Angiology.* 2008;27:319–28.